title: Fearful of Avastin's fate, Genentech asks for unusual hearing.
authors.forename: Mark
authors.initials: M
authors.lastname: Ratner
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001709:Biotechnology; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D004345:Drug Industry; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab